Cardiol Therapeutics Inc.
NASDAQ:CRDLDrug Manufacturers - Specialty & Generic
-$0.01 today
- Market cap
- $114.64M
- Beta
- 0.80
- P/E (TTM)
- -4.5
- EPS (TTM)
- -$0.33
Volume 0.31M
Average 0.68M
CRDL Net Income
Bottom-line profit, the starting point for calculating cash from operations.
Cardiol Therapeutics Inc.NASDAQ: CRDL
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income growth accelerates
Q1 FY2026 net income of CA$10.85M (cash outflow) rose 30.9% year over year, ahead of the +1.7% change in trailing-twelve-month net income. Sequentially, it rose 50.4% from the prior quarter. Over 3 fiscal years it compounded at +3.0% a year.
Context
- Net income grew in size in 1 of the last 3 fiscal years.
What to watch
Whether net income reaches the consensus estimate from 4 analysts of -CA$36.38M (+7.6%) for the fiscal year ending Dec 2026, a step up from the -7.8% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -CA$10.85M+50.4% QoQ
- Last fiscal yearDec 2025
- -CA$33.82M-7.8% YoY
- LTMMar 2026
- -CA$36.38M+1.7% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +30.9% | +33.0% | +2.2 pp |
| 1 year | -7.8% | +7.6% | +15.4 pp |
| 3-year CAGR | +3.0% | -32.1% | -35.2 pp |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
CAD · from the cash flow
- Latest · FY2025
- (33.82M) CAD
- Year-over-year change
- +7.8%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (33.82M) | +7.8% |
| FY2024 | 2024-12-31 | (36.68M) | -30.4% |
| FY2023 | 2023-12-31 | (28.13M) | +9.1% |
| FY2022 | 2022-12-31 | (30.93M) | +2.2% |
| FY2021 | 2021-12-31 | (31.64M) | — |
Net Income vs competitors
How CRDL compares with its peers on the latest reported figures
- Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +1.7% is the 7th highest of 9, against a peer median of +11.1%.
- Over three fiscal years its annual growth of +3.0% compares with a peer median of -0.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2025 | ₪70.93M ILS | +8.1% | — | 29.2% | |
| FY2025 | $55.48M USD | +255.0% | -21.8% | 86687.5% | |
IMAImageneBio Inc | LTM Mar 2026 | $45.07M USD | +8.1% | -8.7% | — |
KLRSKalaris Therapeutics Inc | LTM Mar 2026 | $44.1M USD | — | +41.0% | — |
| LTM Mar 2026 | €41.2M EUR | -7.9% | +14.1% | 140477.1% | |
| LTM Mar 2026 | CA$36.38M CAD | +1.7% | +3.0% | — | |
| LTM Mar 2026 | $35.69M USD | +16.6% | — | 34.9% | |
| LTM Mar 2026 | $34.78M USD | -13.7% | -21.4% | 226.9% | |
| LTM Mar 2026 | $27.09M USD | +14.1% | +24.2% | — | |
| LTM Mar 2026 | $14.21M USD | +21.8% | -0.1% | 13535.2% | |
| Peer median (excluding CRDL) | — | +11.1% | -0.1% | 6881.1% | |
Competitors are the stored peer set for CRDL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (31.64M) | (30.93M) | (28.13M) | (36.68M) | (33.82M) |
| Depreciation & Amortization | 220.42K | 219.91K | 248.36K | 373.11K | 101.98K |
| Deferred Income Tax | (4.92M) | (9.16M) | 0 | 0 | 0 |
| Stock-Based Compensation | 8.5M | 5.01M | 4.16M | 14.28M | 10.7M |
| Change in Working Capital | 76.52K | 5.75M | (545.88K) | (931.57K) | (733.34K) |
| Accounts Receivables | (59.95K) | (144.18K) | 200.33K | (81.75K) | 135.43K |
| Inventory | 17.97K | (4.47M) | 0 | 0 | 0 |
| Accounts Payables | 2.39M | 4.47M | 0 | 0 | 0 |
| Other Working Capital | (2.27M) | 5.89M | (746.2K) | (849.82K) | (868.76K) |
| Other Non-Cash Items | 4.21M | 1.89M | (911.39K) | (2.1M) | (105.34K) |
| Operating Cash Flow | (23.55M) | (27.22M) | (25.18M) | (25.06M) | (23.85M) |
| Capital Expenditures | (12.92K) | (74.71K) | (64.31K) | (21.29K) | (24.48K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (12.92K) | (74.71K) | (64.31K) | (21.29K) | (24.48K) |
| Debt Repayment | (51.92K) | (53.93K) | (55.38K) | (41.53K) | (55.38K) |
| Common Stock Issued | 84.08M | 0 | 0 | 21.36M | 16.07M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 9.41M | (0) | 0 | (2.47M) | (477.03K) |
| Financing Cash Flow | 93.44M | (53.93K) | (55.38K) | 18.84M | 15.54M |
| Effect of Forex Changes | (11.13K) | 2.92M | 762.04K | 1.89M | (824.04K) |
| Net Change in Cash | 69.87M | (24.43M) | (24.54M) | (4.35M) | (9.16M) |
| Free Cash Flow | (23.56M) | (27.3M) | (25.24M) | (25.08M) | (23.88M) |
Cardiol Therapeutics Inc.
NASDAQ:CRDL
Intrinsic Alpha fair value
Locked
Current Price
$0.95
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.